1. Introduction {#sec1}
===============

Noroviruses are the primary cause of epidemic and sporadic acute infectious gastroenteritis among people of all ages worldwide \[[@B1]--[@B4]\]. Norovirus belongs to the family Caliciviridae and has a positive-sense, single-stranded RNA genome of 7.5\~7.7 kb. The genome consists of three open reading frames (ORFs). ORF1 encodes nonstructural proteins such as NTPase, protease, and RNA-dependent RNA polymerase (RdRp). ORF2 encodes the major capsid protein (VP1) and ORF3 encodes the minor capsid protein (VP2). There are six major norovirus genogroups (GI--GVI), defined according to major capsid protein VP1 sequences \[[@B2], [@B5]\]. GI and GII are the most frequently detected genogroups in human infections and GIV is also implicated in human gastroenteritis. Genogroups can be subdivided into genotypes, of which 9 GI and 23 GII capsid genotypes have been described \[[@B1], [@B5]\].

However, genotyping based merely on capsid sequence variations is not sufficient to characterize norovirus because the norovirus genome frequently undergoes recombination, leading to different capsid and polymerase gene types. Thus far, 9 GI and 23 GII capsid genotypes and 14 GI and 29 GII polymerase genotypes have been described and the current nomenclature comprises both polymerase and capsid genotypes \[[@B1], [@B5]\].

The genotypic distribution of norovirus strains showed temporal and geographical fluctuations \[[@B1]--[@B3]\]; thus continuous monitoring is necessary to prevent and control the spread of norovirus outbreaks. Molecular epidemiology data suggest that GII.4 genotype and its variants are the most frequent genotypes, evolve rapidly, and have been associated with many norovirus outbreaks. New GII.4 variants emerge every 2-3 years and become the cause of global epidemics of acute gastroenteritis, including US 1995/96 in the late 1990s, Farmington Hills virus in 2002, Hunter virus in 2004, Den Haag 2006b virus in 2007-2008, New Orleans virus 2009 in 2009--2012, and most recently Sydney 2012 in 2012-2013 \[[@B6]\]. Sequence and structural characterization of the antigenic properties of capsid protein have revealed that the surface-exposed subdomain P2 (residues 279 to 405) interacts with potential neutralizing antibodies and norovirus carbohydrate-binding ligands and that changes in highly variable sites (epitopes A to E) within the P2 subdomain of GII.4 norovirus correlate with the emergence of new epidemic strains \[[@B7]\].

In South Korea, norovirus infection is most prevalent from November to January \[[@B8]\]. One study found that GII.1 was most frequent in Gyeonggi from 2001 to 2005 \[[@B9]\], whereas GII.4 was most frequently identified in most other studies \[[@B6], [@B10], [@B11]\]. Most norovirus genotype studies in Korea have focused only on the capsid, and not polymerase genotypes, and no studies addressed the amino acid composition of the norovirus capsid.

The purpose of this study was to investigate the molecular epidemiology of norovirus at the level of polymerase and capsid genes and to characterize the most frequently detected norovirus strain in Korea in 2013 using phylogenetic, similarity, and capsid epitope analyses.

2. Methods {#sec2}
==========

2.1. Sample Collection {#sec2.1}
----------------------

This study was approved by the Institutional Review Board of Hallym University Dongtan Sacred Heart Hospital (IRB number 2013-030). A total of 2,980 fecal samples from several cities in the Seoul metropolitan area were collected between January and December 2013 and were tested for norovirus antigen at the Department of Laboratory Medicine, Hallym University Dongtan Sacred Heart Hospital. Of these, 349 samples (11.7%) yielded positive results with the RIDASCREEN Norovirus antigen test kit (R-Biopharm, Darmstadt, Germany). Norovirus antigen-positive samples were diluted to a 10% stool suspension in phosphate-buffered saline and stored at −70°C. Some norovirus antigen-positive samples could not be further genotyped because the stool volume was insufficient for additional testing or there was PCR failure. Thus, 230 samples were successfully genotyped between January 2013 and December 2013. For these 230 genotyped norovirus samples, the overall median patient age was 1.7 years (range, 1 week to 74 years), and 193 samples (83.9%) were from patients aged less than 5 years.

2.2. Norovirus PCR and Sequencing {#sec2.2}
---------------------------------

Viral RNA was extracted from 140 *μ*L of the fecal supernatant using a QIAamp Viral RNA Mini Kit according to manufacturer instructions (Qiagen, Hilden, Germany). All primer sets used for norovirus genotyping are summarized in [Table 1](#tab1){ref-type="table"}.

For norovirus polymerase (ORF1, RdRp) genotyping, either one-step RT-PCR or nested RT-PCR was performed using specific primer sets targeting ORF1 encoding polymerase (RdRp): JV12/JV13 \[[@B12]\] or 1st PCR NV32/NV36 and 2nd PCR NV33/NV35 \[[@B13]\].

For norovirus capsid (ORF2, VP1) genotyping, nested RT-PCR was performed as described previously \[[@B5]\]. One-step RT-PCR was performed using the specific primers GI-F1M/GI-R1M and GII-F1M/GII-R1M, which target ORF2 encoding capsid protein (VP1). The second nested PCR was performed with the primers GI-F2/GI-R1M and GII-F3/GII-R1M.

For phylogenetic, similarity, and epitope analyses of the most frequently detected norovirus strain, one-step RT-PCRs targeting the ORF1-ORF2 junction and remaining ORF2 capsid region were performed using specific primers: NV33/G2SKR \[[@B14]\] and GII-F1M/GV132 \[[@B15]\].

PCR products were visualized by agarose gel electrophoresis and analyzed by DNA sequencing. The nucleotide sequences were analyzed using ABI Prism BigDye Terminator version 3.1 (Applied Biosystems, Foster City, CA, USA). Genotyping of the sequences obtained was performed with an automated genotyping tool (available at <http://www.rivm.nl/mpf/norovirus/typingtool> \[[@B16]\]) and GenBank nucleotide BLAST search (<http://blast.ncbi.nlm.nih.gov/>).

2.3. Phylogenetic and Similarity Analyses {#sec2.3}
-----------------------------------------

We performed phylogenetic and similarity analyses to determine the relationship between our most frequently detected norovirus GII.4 strains and representative GII.4 strains. Seven norovirus sequences from GII.4 strains obtained in this study and representative reference GII.4 strains (Farmington Hills 2002/USA/AY502023, Hunter 2004/AU/DQ078814, Den Haag 2006/NL/EF126965, Apeldoorn 2007/AB445395, New Orleans 2009/USA/GU445325, Sydney 2012/AU/JX459908, and Sydney 2012/KR/KM272334), including the closest strain (Sydney 2012/Taiwan/KJ533134), were selected and aligned with MEGA version 6. Reference strain sequences were retrieved from GenBank. The 4331-6660 nucleotide regions in ORF1-ORF2 (polymerase-capsid) region were compared. Phylogenetic and similarity analyses were performed to evaluate the genetic relationships between these sequences. Sites with ambiguous alignments were removed before phylogenetic analysis. The phylogenetic trees were constructed using the neighbor-joining method and different substitution models depending on the genomic region studied, with 1000 bootstraps. Similarity percentages between sequences and reference sequences were assessed with the SimPlot program version 3.5.1.

2.4. Comparison of the Capsid Antigenic Epitopes of the Strains from This Study with Reference Strains {#sec2.4}
------------------------------------------------------------------------------------------------------

Deduced amino acid sequences of norovirus capsid antigens were analyzed and compared to the reference strains. The capsid hypervariable P2 antigenic epitopes (A to E) of the norovirus strains obtained from this study were compared to the reference strains. Multiple sequence alignment and translation to amino acids were conducted using the MEGA version 6 program.

3. Results {#sec3}
==========

3.1. Monthly Norovirus Antigen Positivity Rates {#sec3.1}
-----------------------------------------------

The rates of norovirus antigen positivity between January 2013 and December 2013 are shown by month in [Table 2](#tab2){ref-type="table"}. During 2013, the monthly norovirus antigen positivity rates showed a V-shaped distribution between January (23.6%) and December (32.0%), with the lowest rate detected in August (1.8%). Norovirus infections were observed throughout the year. Positivity rates surpassed 20% in January and in November to December 2013.

3.2. Norovirus Genotype {#sec3.2}
-----------------------

Of the 230 genotyped samples, norovirus GI was detected in four (1.7%) cases and GII in 226 (98.3%) cases ([Table 3](#tab3){ref-type="table"}). Capsid genotyping results showed that GII.4 (77.4%) was the most frequent genotype, followed by GII.3 (6.1%), GII.13 (3.9%), GII.2 (2.6%), GII.6 (2.6%), GII.17 (2.6%), and GII.21 (1.7%). GII.4 Sydney 2012, which has been reported in Australia, New Zealand, Japan, Western Europe, Canada, and the USA, was the predominant genotype during this period, comprising 164/177 norovirus GII.4-positive samples (92.7%), and was detected throughout 2013, except June and July, and its frequency increased in November and December ([Table 2](#tab2){ref-type="table"}). Four samples (1.7%) were of the norovirus GII.4 Den Haag 2006b genotype ([Table 3](#tab3){ref-type="table"}). GII.Pe/GII.4 Sydney 2012 was the most frequent polymerase/capsid genotype (65.7%), followed by GII.P17/GII.17 (2.1%), GII.P21/GII.3 (2.1%), GII.P16/GII.2 (1.7%), GII.P16/GII.13 (1.3%), GII.P4 2006b/GII.4 2006b (0.9%), and GII.P21/GII.21 (0.9%). GII.P17/GII.17 was the second most frequently detected polymerase/capsid genotype in this study. BLAST searches revealed that GII.P17/GII.17 strains in this study, isolated from January to April 2013, were closest to norovirus Hu/GII/CN/2013/GII.P17_GII.17/Nanjing010141 isolated in China in June 2013 and norovirus Hu/GII/JP/2013/GII.P17_GII.17/Saitama5309 isolated in Japan in 2013.

The genotype frequencies of GII.4 Sydney and GII.4 were significantly higher in the group of children less than 5 years of age than in the group of people older than 5 years (79.3% (153/193) versus 56.8% (21/37), *P* \< 0.05). Other genotype frequencies were not significantly different between these two groups.

3.3. Phylogenetic and Similarity Analyses {#sec3.3}
-----------------------------------------

We randomly selected seven samples of GII.Pe/GII.4 Sydney 2012, the most frequent polymerase/capsid genotype collected in 2013, and compared the 4331-6660 nucleotide sequence regions in ORF1-ORF2 (polymerase-capsid). In all samples, the norovirus genotyping tools yielded GII.Pe/GII.4 variant Sydney 2012 as the closest sequence. BLAST analysis identified norovirus 13-Z-2/2012/GII.4 (GenBank accession number KJ533134) as the closest strain (query coverage = 100%, identity = 99%), obtained in Taiwan in February 2013, compared to one of the strains in this study (strain \#1487 isolated in February 2013). The identities between this strain (13-Z-2/2012/GII.4) and the strains in our study were 99.1--99.6%. Phylogenetic trees and SimPlot analysis showed genetic distances among the norovirus reference strains (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}).

3.4. Comparison of Capsid Antigen Epitopes {#sec3.4}
------------------------------------------

The deduced amino acid sequences of the A--E epitopes of the capsid P2 domain of representative reference GII.4 strains and the strains in this study are shown in [Table 4](#tab4){ref-type="table"}. The amino acids of A--E epitopes of the norovirus strains analyzed in this study were very similar between the strains, with the exception of residues 373 (beside epitope A) and 393 (in epitope D). The original amino acid at position 393 of norovirus GII.4 Sydney 2012 was glycine (G), detected in some of our strains. Serine (S) was encoded at this position in other strains, which was the same amino acid in the New Orleans 2009 strain.

4. Discussion {#sec4}
=============

In this study, we investigated the epidemiology of norovirus infections and the genetic diversity of norovirus strains circulating in metropolitan areas of Korea in 2013. Norovirus infections varied seasonally (monthly positive rate: 1.8\~32.0%) and the number of norovirus infections in this study increased in late autumn and winter (January, November, and December), similar to the findings of previous studies in Korea \[[@B8]\] and other countries north of the equator (<http://www.cdc.gov/norovirus/>). In countries south of the equator, norovirus activity increases around August, also in winter (<http://www.cdc.gov/norovirus/>). Thus, norovirus infection is most common in cold seasons.

The most frequently detected norovirus polymerase/capsid genotype in this study was classified as GII.Pe/GII.4 Sydney 2012. The GII.4 Sydney 2012 capsid genotype, first reported in Australia in 2012, caused the global outbreak of 2012-2013 \[[@B3]\] and replaced the GII.4 New Orleans 2009 strain. The GII.Pe polymerase genotype was first detected in the norovirus outbreak of 2008 in Victoria, Australia, and then at lower frequencies in 2009 and 2010 before becoming the predominant genotype in 2012 \[[@B17]\]. GII.Pe was linked to the GII.3, GII.4, and GII.12 capsid genotypes \[[@B17]\]. Thus, GII.Pe/GII.4 Sydney 2012 is a recombinant of GII.Pe polymerase and GII.4 capsid gene variant sharing sequences with Apeldoorn 2008 and New Orleans 2009 \[[@B3]\].

BLAST searches revealed that norovirus 13-Z-2/2012/GII.4 collected in Taiwan in February 2013 was closest to a GII.Pe/GII.4 Sydney 2012 isolated from this study, also collected in February 2013. Thus, similar GII.Pe/GII.4 Sydney 2012 strains were active in Korea and Taiwan at the same time. The identities between this strain (13-Z-2/2012/GII.4) and the GII.Pe/GII.4 Sydney 2012 strains identified in our study were 99.1--99.6%. Thus, similar GII.Pe/GII.4 Sydney 2012 strains were the main cause of norovirus infection in 2013.

Recombination in the region between ORF1 polymerase and ORF2 capsid is common in norovirus infection. The polymerase-capsid recombination of GII.P16/GII.2, GII.P21/GII.3, GII.P12/GII.3, GII.P16/GII.13, and GII.Pe/GII.3 found in this study has been reported elsewhere \[[@B17], [@B18]\]. The GII.P17/GII.17 was the second most frequently detected polymerase/capsid genotype in this study. BLAST searches revealed that GII.P17/GII.17 strains in this study, isolated from January to April 2013, were closest to norovirus Hu/GII/CN/2013/GII.P17_GII.17/Nanjing010141 isolated in China in June 2013 and norovirus Hu/GII/JP/2013/GII.P17_GII.17/Saitama5309 isolated in Japan in 2013. Thus, similar GII.P17/GII.17 strains were active in Korea, China, and Japan in 2013. The sequences of these strains were slightly different from those of a novel GII.P17-GII.17 norovirus strain (GII.17 Kawasaki 2014), which emerged as a major cause of gastroenteritis outbreaks in China and Japan in the winter of 2014/2015 \[[@B19]\]. From these findings, we can assume that a novel escape mutant derived from the 2013 GII.P17-GII.17 strains in this study emerged and caused gastroenteritis outbreaks in China and Japan in the winter of 2014/2015.

The genotype frequency of GII.4 Sydney or GII.4 was significantly higher in the group of children aged less than 5 years than in the group of people older than 5 years \[79.3% (153/193) versus 56.8% (21/37), *P* \< 0.05\]. Other genotypes were not significantly different between the two age groups. This could be because GII.4 Sydney norovirus was predominant during this period, and the immunity of children to norovirus infection is weaker than that of adults; furthermore, the children usually stayed in childcare facilities in Korea.

Antigenic variation in GII.4 is an important contributor to the emergence of novel pandemic noroviruses \[[@B20]\], with most variants appearing in five evolving blockade epitopes (A--E) within the capsid P2 domain \[[@B7]\]. In this study, the A--E epitopes were similar with the exception of the residues at positions 373 (adjacent to epitope A) and 393 (epitope D). Mutations at positions 333, 340, and 393 of the capsid protein likely played a role in the evolution/adaptation or escape from herd immunity to the novel pandemic GII.4 variant \[[@B21]\]. It is also possible that other, not yet identified, mechanisms were also involved. Further studies on the evolutionary pathway of new GII.4 variants will be needed to predict the emergence of new pandemic strains and to guide vaccine development.

5. Conclusions {#sec5}
==============

In summary, increased norovirus activity in Korea in 2013 was related to the emergence of a norovirus GII.4 variant, GII.Pe/GII.4 Sydney 2012, similar to the findings in global epidemics. Epitope analysis showed at least one amino acid difference in comparison to previous GII.4 reference strains. These data improve our knowledge in relation to viral evolution, outbreak predictions, and vaccine development. As new GII.4 variants emerge every 2-3 years and cause global epidemics, continuous monitoring of new norovirus GII.4 variants will be needed to predict the emergence of new pandemic strains and to guide vaccine development.
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![Phylogenetic tree based on partial nucleotide sequences of norovirus GII.4 ORF1 and ORF2. Seven samples of GII.Pe/GII.4 Sydney 2012 genotype in this study were compared to other representative GII.4 reference strains. The sequences of the region comprising nucleotide 4331-6660 were compared. The scale bar represents genetic distance (expressed as nucleotide substitutions per site).](BMRI2015-468304.001){#fig1}

![SimPlot analysis for nucleotide similarity between the GII.4 Sydney strains in this study and other previously reported GII.4 Sydney strains and other GII.4 variants causing pandemics. The sequence of one strain in this study served as a query strain. The sequences of the regions comprising nucleotide 4331-6660 were compared.](BMRI2015-468304.002){#fig2}

###### 

Primers used in this study for the RT-PCR and sequencing of norovirus.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Targeted gene                  Reaction type                    Primer name                      Primer orientation           Primer sequence (5′ to 3′)        Annealing position   PCR product size
  -------------------- --------- -------------------------------- -------------------------------- ---------------------------- --------------------------------- -------------------- ------------------
  ORF1\                1         One-step RT-PCR                  JV12                             F                            ATA CCA CTA TGA TGC AGA TTA       nt 4552              327 bp
  (polymerase, RdRp)                                                                                                                                                                   

  JV13                 R         TCA TCA TCA CCA TAG AAA GAG      nt 4878                                                                                                              

  2                    1st PCR   NV32                             F                                ATG AAT ATG AAT GAA GAT GG   nt 4226                           501 bp               

  NV36                 R         ATT GGT CCT TCT GTT TTG TC       nt 4726                                                                                                              

  Nested PCR           NV33      F                                TAC CAC TAT GAT GCA GAT TA       nt 4280                      357 bp                                                 

  NV35                 R         GTT GAC ACA ATC TCA TCA TC       nt 4636                                                                                                              

                                                                                                                                                                                       

  ORF2\                1 (GI)    1st PCR                          GI-F1M                           F                            CTG CCC GAA TTY GTA AAT GAT GAT   nt 5342              330 bp
  (capsid, VP1)                                                                                                                                                                        

  GI-R1M               R         CCA ACC CAR CCA TTR TAC ATY TG   nt 5671                                                                                                              

  Nested PCR           GI-F2     F                                ATG ATG ATG GCG TCT AAG GAC GC   nt 5357                      315 bp                                                 

  GI-R1M               R         CCA ACC CAR CCA TTR TAC ATY TG   nt 5671                                                                                                              

  2 (GII)              1st PCR   GII-F1M                          F                                GGG AGG GCG ATC GCA ATC      nt 5058                           344 bp               

  GII-R1M              R         CCR CCT GCA TRI CCR TTR TAC AT   nt 5401                                                                                                              

  Nested PCR           GII-F3    F                                TTG CCR GCA TRI CCR TTR TAC AT   nt 5088                      314 bp                                                 

  GII-R1M              R         CCR CCT GCA TRI CCR TTR TAC AT   nt 5401                                                                                                              

                                                                                                                                                                                       

  ORF1-ORF2 junction             One-step RT-PCR                  NV33                             F                            TAC CAC TAT GAT GCA GAT TA        nt 4280              1110 bp

  G2SKR                R         CCR CCN GCA TRH CCR TTR TAC AT   nt 5389                                                                                                              

                                                                                                                                                                                       

  ORF2 (capsid, VP1)             One-step RT-PCR                  GII-F1M                          F                            GGG AGG GCG ATC GCA ATC           nt 5049              1681 bp

  GV132                R         CCR GCR AAG AAA GCR CCA GCC AT   nt 6729                                                                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

F, forward; R, reverse.

###### 

Norovirus antigen positivity and GII.4 strain frequencies by month.

  Date        Number (No.) of specimens tested   Number (%) of norovirus antigen-positive specimens   Number of genotyped specimens   Number (%) of GII.4 strains of genotyped specimens   Number (%) of GII.4 Sydney 2012 strains of genotyped specimens
  ----------- ---------------------------------- ---------------------------------------------------- ------------------------------- ---------------------------------------------------- ----------------------------------------------------------------
  Jan. 2013   225                                53 (23.6%)                                           33                              25 (75.8%)                                           22 (66.7%)
  Feb.        300                                38 (12.7%)                                           28                              19 (67.9%)                                           14 (50.0%)
  Mar.        252                                27 (10.7%)                                           17                              8 (47.1%)                                            7 (41.2%)
  Apr.        256                                16 (6.3%)                                            10                              3 (30.0%)                                            3 (30.0%)
  May         247                                11 (4.5%)                                            2                               1 (50.0%)                                            1 (50.0%)
  Jun.        218                                6 (2.8%)                                             1                               0 (0%)                                               0 (0%)
  Jul.        237                                5 (2.1%)                                             2                               0 (0%)                                               0 (0%)
  Aug.        225                                4 (1.8%)                                             1                               1 (100%)                                             1 (100%)
  Sep.        260                                11 (4.2%)                                            8                               8 (100%)                                             7 (87.8%)
  Oct.        138                                8 (5.8%)                                             5                               3 (60.0%)                                            3 (60.0%)
  Nov.        284                                62 (21.8%)                                           49                              47 (95.9%)                                           47 (95.9%)
  Dec.        338                                108 (32.0%)                                          74                              62 (83.4%)                                           59 (79.7%)
  Total       2,980                              349 (11.7%)                                          230                             177 (77.0%)                                          164 (71.3%)

###### 

Norovirus polymerase and capsid genotypes.

  Polymerase (RdRp) genotype   Capsid (VP1) genotype   Number (%)
  ---------------------------- ----------------------- -------------
  Nontyped                     GI.3                    1 (0.4%)
  GI.P4                        GI.4                    1 (0.4%)
  Nontyped                     GI.6                    2 (0.9%)
  GII.P16                      GII.2                   4 (1.7%)
  Nontyped                     GII.2                   2 (0.9%)
  GII.P21                      GII.3                   5 (2.1%)
  GII.P12                      GII.3                   1 (0.4%)
  GII.Pe                       GII.3                   1 (0.4%)
  Nontyped                     GII.3                   7 (3%)
  GII.P4 Den Haag 2006b        GII.4 Den Haag 2006b    2 (0.9%)
  Nontyped                     GII.4 Den Haag 2006b    2 (0.9%)
  GII.Pe                       GII.4 Sydney 2012       151 (65.7%)
  Nontyped                     GII.4 Sydney 2012       14 (6.1%)
  GII.Pe                       GII.4                   5 (2.1%)
  Nontyped                     GII.4                   4 (1.7%)
  Nontyped                     GII.5                   1 (0.4%)
  Nontyped                     GII.6                   6 (2.6%)
  GII.P8                       GII.8                   1 (0.4%)
  Nontyped                     GII.8                   1 (0.4%)
  GII.P16                      GII.13                  3 (1.3%)
  Nontyped                     GII.13                  6 (2.6%)
  GII.P17                      GII.17                  5 (2.1%)
  Nontyped                     GII.17                  1 (0.4%)
  GII.P21                      GII.21                  2 (0.9%)
  Nontyped                     GII.21                  2 (0.9%)
                               Total                   230 (100%)

###### 

Deduced amino acid sequence of capsid antigen epitopes A to E of the norovirus GII.4 variants.

  GII.4 variant                               Epitope A   Epitope B   Epitope C   Epitope D   Epitope E                                                       
  ------------------------------------------- ----------- ----------- ----------- ----------- ----------- --- ------- --- --- --- --- ------- --- --- --- --- -------
  Farmington Hills 2002/USA/AY502023          A           T           H           N           N           N   N       M   K   G   E   N       G   A   S   T   G
  Hunter 2004/AU/DQ078814                     A           A           Q           N           S           S   N       V   R   R   E   S       T   T   D   D   S
  Den Haag 2006b/NL/EF126965                  A           S           R           N           S           E   N       V   K   G   E   S       T   T   S   N   V
  Apeldoorn 2007/NL/AB445395                  T           S           R           N           A           D   N       V   K   T   D   D       T   A   S   N   N
  New Orleans 2009/USA/GU445325               P           S           R           N           A           D   N       V   K   T   E   S       T   T   S   N   I
                                                                                                                                                              
  Sydney 2012/AU/JX459908_2012.03             **T**       S           R           N           **E**       D   **R**   V   K   T   E   **G**   T   T   S   N   **T**
  Sydney 2012/KR/KM272334_12.08.04            **T**       S           R           N           **E**       D   **H**   V   K   T   E   **G**   T   T   S   N   **T**
  Sydney 2012/Hong Kong/KC631827_12.12.10     **T**       S           R           N           **E**       D   **H**   V   K   T   E   **S**   T   T   S   N   **T**
  Sydney 2012/Taiwan/KJ533134_13.02           **T**       S           R           N           **E**       D   **R**   V   K   T   E   **S**   T   T   S   N   **T**
  Sydney 2012 in this study \#88_13.01.18     **T**       S           R           N           **E**       D   **R**   V   K   T   E   **G**   T   T   S   N   **T**
  Sydney 2012 in this study \#280_13.02.08    **T**       S           R           N           **E**       D   **R**   V   K   T   E   **S**   T   T   S   N   **T**
  Sydney 2012 in this study \#327_13.02.12    **T**       S           R           N           **E**       D   **R**   V   K   T   E   **S**   T   T   S   N   **T**
  Sydney 2012 in this study \#1487_13.11.01   **T**       S           R           N           **E**       D   **R**   V   K   T   E   **G**   T   T   S   N   **T**
  Sydney 2012 in this study \#1497_13.11.04   **T**       S           R           N           **E**       D   **R**   V   K   T   E   **S**   T   T   S   N   **T**
  Sydney 2012 in this study \#1682_13.12.26   **T**       S           R           N           **E**       D   **R**   V   K   T   E   **G**   T   T   S   N   **T**
  Sydney 2012 in this study \#1696_13.12.27   **T**       S           R           N           **E**       D   **H**   V   K   T   E   **S**   T   T   S   N   **T**
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